Updated on 26 September 2014
Non-Hodgkin Lymphoma (NHL) treatment market in APAC was $1.1 bn in 2013
Singapore: Non-Hodgkin Lymphoma (NHL) treatment market in Asia-Pacific (APAC) countries including India, Australia, China and Japan will expand from $1.1 billion in 2013 to $1.7 billion by 2020, according to business intelligence provider GBI Research.
According to company's latest report, Japan had a 67.2 percent share of the APAC region's NHL therapeutics market in 2013. While this will dip slightly to 64.7 percent, the country's NHL market by value will reach approximately $1.1 billion by 2020.
Ms Sravanthi Addapally, analyst, GBI Research, said, "Japan's expected growth will be largely attributable to a rapidly aging population and increased NHL incident cases, as well as the launch of new targeted therapies to treat previously underserved patient segments with numerous unmet needs.
"Among the expected launches, ibrutinib for indolent NHL and everolimus for Diffuse Large B-Cell Lymphoma will increase the overall treatment costs and drive growth. The anticipated launches of monoclonal antibodies, such as Roche's obinutuzumab, will also significantly boost the market." The analyst adds that the approval of additional indications for Adcetris and the launch of the Imunomax-γ, which is currently awaiting approval in Japan for mycosis fungoides/Sezary syndrome, will have a further positive impact.